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Lynch syndrome, also known as hereditary nonpolyposis colon 
cancer syndrome (1), is a rare, autosomal, dominantly inherited 
syndrome caused by germline mutations in DNA mismatch repair 
genes, which confer substantial risks for cancers of the colorectum 
and endometrium and increased risks for cancers of the stomach, 
small intestine, hepatobiliary system, kidney, ureter, ovary, and 
sebaceous tumors (2,3). Mutations in the mismatch repair genes, 
MLH1 and MSH2, account for 70%–80% of all Lynch syndrome 
colorectal cancers (ie, colorectal cancers occurring in people with 
germline DNA mismatch repair gene mutations) (4–7).
Mutations in MSH6 account for 10%–20% of Lynch syndrome 
colorectal cancers and 0.4% of all colorectal cancers (4–7), with 
the greater proportion of colorectal cancer diagnosed at a 
younger age (4,6). The prevalence of MSH6 mutations in women 
with endometrial cancer who were not selected for family history 
is less well established with estimates ranging from 1.0% to 3.8% 
(8–12).
Few studies have attempted to estimate the age-specific cumu-
lative cancer risk for carriers of germline mutations in MSH6 
(penetrance) (13–18), so information on the consequences of such 
mutations remains uncertain. Most of these studies (13–16) have 
analyzed data from families that were ascertained because of a 
strong family history of cancers related to Lynch syndrome, or 
preferentially mutation-tested individuals with colorectal cancer 
over individuals without colorectal cancer, and appear not to have 
correctly taken into account the ascertainment when deriving their 
penetrance estimates. Recruiting families from family cancer 
clinics will result in oversampling of family members who have 
been diagnosed with colorectal or other cancers, and such recruit-
ment has been shown to result in inflated estimates of cancer risks 
Article
risks of lynch Syndrome cancers for MSH6 Mutation carriers
Laura Baglietto, Noralane M. Lindor, James G. Dowty, Darren M. White, Anja Wagner, Encarna B. Gomez Garcia, Annette  
H. J. T. Vriends, Dutch Lynch Syndrome Study Group, Nicola R. Cartwright, Rebecca A. Barnetson, Susan M. Farrington, 
Albert Tenesa, Heather Hampel, Daniel Buchanan, Sven Arnold, Joanne Young, Michael D. Walsh, Jeremy Jass, Finlay Macrae, 
Yoland Antill, Ingrid M. Winship, Graham G. Giles, Jack Goldblatt, Susan Parry, Graeme Suthers, Barbara Leggett, Malinda Butz, 
Melyssa Aronson, Jenny N. Poynter, John A. Baron, Loic Le Marchand, Robert Haile, Steve Gallinger, John L. Hopper, 
John Potter, Albert de la Chapelle, Hans F. Vasen, Malcolm G. Dunlop, Stephen N. Thibodeau, Mark A. Jenkins
Manuscript received June 9, 2009; revised November 10, 2009; accepted November 17, 2009.
Correspondence to: Noralane M. Lindor, MD, E7B, Mayo Foundation, Rochester, MN 55905 (e-mail: nlindor@mayo.edu).
 Background Germline mutations in MSH6 account for 10%–20% of Lynch syndrome colorectal cancers caused by hereditary 
DNA mismatch repair gene mutations. Because there have been only a few studies of mutation carriers, their 
cancer risks are uncertain.
 Methods We identified 113 families of MSH6 mutation carriers from five countries that we ascertained through family can-
cer clinics and population-based cancer registries. Mutation status, sex, age, and histories of cancer, polypectomy, 
and hysterectomy were sought from 3104 of their relatives. Age-specific cumulative risks for carriers and hazard 
ratios (HRs) for cancer risks of carriers, compared with those of the general population of the same country, were 
estimated by use of a modified segregation analysis with appropriate conditioning depending on ascertainment.
 Results For MSH6 mutation carriers, the estimated cumulative risks to ages 70 and 80 years, respectively, were as fol-
lows: for colorectal cancer, 22% (95% confidence interval [CI] = 14% to 32%) and 44% (95% CI = 28% to 62%) for 
men and 10% (95% CI = 5% to 17%) and 20% (95% CI = 11% to 35%) for women; for endometrial cancer, 26% 
(95% CI = 18% to 36%) and 44% (95% CI = 30% to 58%); and for any cancer associated with Lynch syndrome, 24% 
(95% CI = 16% to 37%) and 47% (95% CI = 32% to 66%) for men and 40% (95% CI = 32% to 52%) and 65% (95% 
CI = 53% to 78%) for women. Compared with incidence for the general population, MSH6 mutation carriers had 
an eightfold increased incidence of colorectal cancer (HR = 7.6, 95% CI = 5.4 to 10.8), which was independent of 
sex and age. Women who were MSH6 mutation carriers had a 26-fold increased incidence of endometrial can-
cer (HR = 25.5, 95% CI = 16.8 to 38.7) and a sixfold increased incidence of other cancers associated with Lynch 
syndrome (HR = 6.0, 95% CI = 3.4 to 10.7).
 Conclusion We have obtained precise and accurate estimates of both absolute and relative cancer risks for MSH6 mutation 
carriers.
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if this ascertainment is not fully taken into account (19). For pop-
ulation-based studies, the appropriate adjustment for ascertain-
ment is straightforward. A meta-analysis (18) of 10 MSH6 mutation 
families extracted from two population-based studies (17,20) esti-
mated that the cumulative colorectal cancer risk to age 70 years 
was similar for men and women at approximately 35%. For endo-
metrial cancer, the cumulative risk was approximately 35% to age 
70 years and 50% to age 80 years. In this analysis, we combined 
data from 113 families with deleterious germline MSH6 mutations 
and estimated the cancer risks for mutation carriers by use of sta-
tistical methods that appropriately condition on ascertainment.
Participants and Methods
Study Population
The study population was composed of families that carried dele-
terious MSH6 mutations, which were defined as variants that were 
predicted to result in a stop codon, a frameshift mutation, a large 
insertion or deletion, or a missense mutation that was judged to be 
deleterious. Families were obtained from four sources: 1) the 
Colon Cancer Family Registry, which recruited colorectal cancer 
families from the United States, Canada, Australia, and New 
cONteXt AND cAVeAtS
Prior knowledge
Germline mutations in MSH6 account for 10%–20% of Lynch 
syndrome colorectal cancers and approximately 0.4% of all colo-
rectal cancers.
Study design
Families of MSH6 mutation carriers from five countries were iden-
tified through family cancer clinics and population-based cancer 
registries. Mutation status; sex; age; and histories of cancer, 
polypectomy, and hysterectomy were sought from their relatives. 
Age-specific cumulative risks of all Lynch syndrome cancers 
among carriers were estimated.
Contribution
MSH6 mutation carriers had high estimated cumulative risks to age 
80 years for colorectal cancer, endometrial cancer, and any cancer 
associated with Lynch syndrome. Compared with incidence for the 
general population, MSH6 mutation carriers had an eightfold 
increased incidence of colorectal cancer that was independent of 
sex and age. Women who were MSH6 mutation carriers had a 
26-fold increased incidence of endometrial cancer and a sixfold 
increased incidence of other cancers associated with Lynch 
syndrome.
Implications
The elevated risks for Lynch syndrome cancers in MSH6 mutation 
carriers differed by sex of the carrier and continued into older age. 
Screening for Lynch syndrome cancers in MSH6 mutation carriers 
is warranted.
Limitations
No haplotype analysis was done for any of the mutations identified 
in more than one family.
From the Editors
 
Zealand; 2) a research consortium in the Netherlands; 3) a research 
group in Scotland; and 4) a research group in Columbus, Ohio. 
Probands, who were defined as the first person in the family to be 
identified with a mutation in MSH6, were ascertained via popula-
tion-based cancer registries (ie, population-based probands) or 
from family genetic services or cancer clinics (ie, clinic-based pro-
bands). From these sources, 113 families of MSH6 mutation car-
riers were ascertained for this study. Mutation status; sex; age; and 
histories of cancer, polypectomy, and hysterectomy were sought 
from the 3104 relatives of the 113 MSH6 mutation–carrying pro-
bands. Written informed consent was obtained, and this research 
was approved by local institutional review boards at each recruiting 
source.
Colon Cancer Family Registry. Details of recruitment methods 
have been described previously (21). All probands and families in 
this study were recruited from January 1, 1997, through December 
31, 2002. For clinic-based ascertainment, the probands were se-
lected from multiple-case colorectal or Lynch syndrome cancer 
families who attended cancer clinics in the United States (Mayo 
Clinic, Rochester, Minnesota; and Cleveland) and Australasia 
(Melbourne, Adelaide, Perth, Brisbane, Sydney, Australia; and 
Auckland, New Zealand). Probands were not required to have 
colorectal cancer. For population-based ascertainment, probands 
were defined as patients with newly diagnosed colorectal cancer 
who were identified by population-based cancer registries in the 
United States (Puget Sound, Washington; the State of Minnesota; 
Los Angeles, California; Arizona; Colorado; New Hampshire; 
North Carolina; and Hawaii), Australia (Victoria), and Canada 
(Ontario). Most population-based sampling was independent of 
family history but in some instances was stratified by family his-
tory. Relatives were recruited via the probands. Selection of pro-
bands for MSH6 gene analysis was based on the absence of MSH6 
protein expression in tumor tissue. The immunohistochemistry 
staining protocol has been described previously (22). Mutation 
analysis of the MSH6 gene was performed by DNA sequence 
analysis. Briefly, all 10 exons and flanking intron sequences of 
MSH6 were amplified from genomic DNA in eight amplicons di-
vided into two multiplex polymerase chain reactions. Primers were 
designed from the MSH6 human genomic sequence (GenBank 
accession number NT_022184) and are available from the authors 
upon request. Polymerase chain reaction multiplex-1 amplified 
exons 2, 5, 6, 7, and 8–10 and multiplex-2 amplified exons 1, 3, and 
4. Electrophoresis was performed on the ABI 3730 (Applied 
Biosystems Inc, Foster City, CA). Sequence chromatograms were 
analyzed by use of Mutation Surveyor (SoftGenetics, State College, 
PA) software. Large insertions and deletions were detected by 
multiplex ligation-dependent probe amplification (23).
Netherlands. Details of recruitment methods have been described 
previously (24). Probands were selected from families suspected of 
having Lynch syndrome by the Dutch Lynch Syndrome Study 
Group from a national registry for families with hereditary non-
polyposis colon cancer established in the Netherlands in 1987. 
Clinical information including age at diagnosis of cancer, site of 
the tumor, and age at and cause of death was collected by the reg-
istry. Most probands were tested for MSH6 mutations depending 
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on tumor microsatellite instability or mismatch repair protein ex-
pression. Polymerase chain reaction was used to amplify DNA. 
In most laboratories in the Netherlands, indirect techniques such 
as denaturing gradient gel electrophoresis, protein truncation test, 
or more recently high-resolution melting curve analysis are, or 
were, used to identify DNA variants. The fragments with variants 
are subsequently analyzed by a direct DNA sequence analysis as 
described above, and deletions and duplications were identified by 
use of multiplex ligation-dependent probe amplification (13).
Scotland. Details of recruitment methods have been described 
previously (6). All probands and families in this study were 
recruited from January 1, 1999, through December 31, 2003. 
Probands were identified from the Scottish Cancer Registry and 
were defined as patients with newly diagnosed colorectal cancer or 
endometrial cancer who were younger than 55 years when diag-
nosed and whose cancer was diagnosed in Scotland. Relatives were 
recruited via the probands.
All probands were tested for MSH6 mutations irrespective of 
tumor microsatellite instability or mismatch repair protein expres-
sion. Mutation analysis of the MSH6 gene was performed by DNA 
sequence analysis, and large insertions and deletions were detected 
by multiplex ligation-dependent probe amplification (6).
Ohio. Details of recruitment methods have been described previ-
ously (5,9). Probands were defined as individuals with newly diag-
nosed adenocarcinoma of the colorectum or endometrium, 
regardless of age or family history of cancer, who were treated at 
one of six major participating hospitals in Columbus, Ohio, in-
cluding the Ohio State University Medical Center (the James 
Cancer Hospital and the Ohio State University East), Mount 
Carmel East, Mount Carmel West, St Ann’s Hospital, Riverside 
Methodist Hospital, and Grant Medical Center. In total, 1566 
patients with colorectal cancer were recruited from January 1, 
1999, through August 31, 2004.
All probands with colorectal or endometrial cancer with micro-
satellite instability were tested for germline mutations in MSH6. 
Mutation analysis of the MSH6 gene was performed by DNA 
sequence analysis, and large insertion and deletions were detected 
by multiplex ligation-dependent probe amplification (5,9).
Data Collection
Information on demography, personal and family history of can-
cer, cancer screening, and cancer surgery was obtained from all 
participants by interview, questionnaire, or extraction from clinical 
records. Efforts were made to verify reported cancer diagnoses by 
use of multiple sources, including family reporting, pathology 
reports, medical records, and death certificates. All probands and 
selected relatives were asked to provide a blood sample for DNA 
analysis and to sign a consent to allow us to retrieve archived 
colorectal cancer tissue.
Statistical Analysis
We estimated the age-specific cumulative risk (penetrance) and the 
age-specific hazard ratios (HRs) for mutation carriers compared 
with the population for the following cancer groups: colorectal 
cancer, endometrial cancer, all other Lynch cancers (ie, gastric, 
small bowel, kidney, ureter, brain, and ovarian cancers) combined, 
all Lynch cancers combined, breast cancer, prostate cancer, all 
non-Lynch cancers combined, and all cancers combined. For colo-
rectal cancer, we censored each individual at the age of polypec-
tomy (except when it occurred within a year of the diagnosis of 
colorectal cancer) and, for endometrial cancer, we censored each 
woman at the age of hysterectomy (except when it occurred within 
a year of the diagnosis of endometrial cancer).
Penetrance for carriers was estimated with a likelihood-based 
approach as in Schaid et al. (25). Cumulative risks to age t years were 
assumed to be logistic functions of t,
α β
α β
    
exp( )
(t)
1 exp( )
t
F
t
where estimates for the parameters a and b and the corresponding 
standard errors and correlations were obtained by use of asymp-
totic maximum likelihood theory. A 95% confidence interval (CI) 
for the cumulative risk to any age t was obtained by simulation.
The hazard ratio was estimated with a likelihood-based approach 
that used a model in which the age-specific hazard for a mutation 
carrier developing any of the above classes of cancer was assumed 
to be the estimated hazard ratio times the sex-, country-, and age-
specific population incidence for the appropriate cancer group. 
Average age-specific population incidences in 1998–2002 for each 
country were obtained from Cancer Incidence in Five Continents (26). 
Hazard ratios were estimated for each cancer group, each sex, and 
each age category (as decades of age or as <50 vs ≥50 years), type of 
mutation (point mutations, small insertions or deletions, and large 
rearrangements), and ascertainment type (population-based vs clin-
ic-based). More than 90% of families were white, making any com-
parison in risks with non-white populations underpowered.
For both the penetrance and the hazard ratios analyses, we cor-
rected for ascertainment by conditioning the likelihood for each 
pedigree, which was sampled independently of family cancer history, 
on the proband’s MSH6 mutation status, cancer status, and age at 
diagnosis. The likelihood for each clinic-based pedigree (which was 
assumed to be ascertained because there was a family history of 
cancer) and for each population-based pedigree (which was ascer-
tained because there was a family history of colorectal cancer) was 
conditioned on the MSH6 mutation status of the proband and the 
cancer status and age at censoring (if unaffected) or diagnosis (if af-
fected) of the proband and all relatives (27). For the analyses, we 
included all first- and second-degree relatives for population-based 
families who were ascertained irrespective of family history; for all 
other families, all available relatives were included.
To gauge the number of mutation carriers in our study, we 
estimated the number of carriers in the 131 families by using the 
laws of Mendelian inheritance to calculate carrier probabilities for 
every ungenotyped individual that was based on the known family 
structure and mutation statuses of relatives. The estimated number 
of carriers was calculated by summing the number of known car-
riers and the carrier probabilities of the ungenotyped relatives.
For each cancer group, 10-year cancer risks for carriers who 
have not previously been diagnosed with the disease were esti-
mated as [R(t + 10) 2 R(t)]/[1 2 R(t)], where t is the carrier’s age in 
years and R(t) and R(t + 10) are the relevant cumulative risks to ages 
t and t + 10 years, respectively. Pedigree analyses were performed 
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with the pedigree analysis program MENDEL [Lange et al. (28)] 
and other calculations in Stata (Stata Corp, College Station, TX) 
version 10 (29).
results
Among the probands of the 113 families with an identified 
mutation in MSH6, 31 carried a point mutation, 77 carried a 
small insertion or deletion, and five carried a large insertion or 
deletion. There were 74 distinct mutations of which, 22 were 
observed across more than one family (range = two to six families) 
(Supplementary Table 1, available online).
Among the 113 probands, 42 were sampled from population-
based sources that were independent of their family history or 
cancer status, six were sampled from population-based sources 
because of family history of cancer, and 65 were ascertained from 
clinic-based sources. The personal cancer history of the probands 
included 61 with colorectal cancer only, 33 with endometrial can-
cer only, 10 with colorectal and endometrial cancers, two with 
ovarian cancer only, two with colorectal and ovarian cancers, one 
with endometrial and ovarian cancers, one with small bowel can-
cer, and three with no cancer. Mean age at colorectal cancer diag-
nosis of affected probands was 52 years (SD = 10 years; range = 26–82 
years). Mean age at endometrial cancer of affected probands was 
51 years (SD = 9 years; range = 31–69 years).
The 48 population-based families included an average of 18.5 
relatives per proband and contributed 15 742 person-years for an 
estimated 346 mutation carriers; the 65 clinic-based families in-
cluded an average of 19.8 relatives per proband and contributed 
35 544 person-years for an estimated 697 mutation carriers (Table 1). 
In total (excluding probands), the families contain an estimated 
1043 mutation carriers who contributed 51 286 person-years. 
Definitive mutation status was known for all probands and for 278 
relatives who were carriers and 247 who were noncarriers.
The colorectal cancer family history of the first- and second-
degree relatives of the 42 population-based probands who were 
ascertained independent of their family cancer history was as fol-
lows: 18 (43%) had no affected relative, 14 (33%) had one affected 
relative, seven (17%) had two affected relatives, and three (7%) 
had three or more affected relatives. Thirty had a family cancer 
history that did not meet the Amsterdam II criteria (30), and of the 
remaining 12 (29%) who had a family cancer history meeting the 
Amsterdam II criteria, four met the Amsterdam I criteria (30).
Among the relatives of all 48 population-based MSH6 mutation 
probands, 37 had colorectal cancer (an average of 0.8 per family), 
22 had endometrial cancer (an average of 0.5 per family), and 19 
had another Lynch syndrome cancer (an average of 0.4 per family), 
for a total of 78 Lynch syndrome cancers (an average of 1.6 per 
family) (Table 2). Among the relatives of all 65 clinic-based fam-
ilies, 111 had colorectal cancer (an average of 1.7 per family), 49 
had endometrial cancer (an average of 0.8 per family), and 28 had 
another Lynch cancer (an average of 0.4 per family), for a total of 
188 Lynch syndrome cancers (an average of 2.9 per family).
Table 3 and Figure 1 show that, by age 70 years, we estimate 
that 22% (95% CI = 14% to 32%) of MSH6 mutation carriers who 
were men would be diagnosed with colorectal cancer compared 
with 10% (95% CI = 5% to 17%) of MSH6 mutation carriers who 
were women. By age 80 years, we estimated that 44% (95% 
CI = 28% to 62%) of MSH6 mutation carriers who were men 
would be diagnosed with colorectal cancer, and this was greater 
than the estimate of 20% (95% CI = 11% to 35%) of MSH6 muta-
tion carriers who were women. The 10-year risks of colorectal 
cancer for MSH6 mutation carriers without a previous colorectal 
cancer diagnosis at age 70 years were 28% (95% CI = 16% to 45%) 
for men and 11% (95% CI = 4% to 23%) for women. The 10-year 
risks at other ages were 6% (95% CI = 3% to 9%) at age 50 years 
and 14% (95% CI = 8% to 22%) at age 60 years for men and 3% 
(95% CI = 1% to 5%) at age 50 years and 5% (95% CI = 3% to 
11%) at age 60 years for women (Table 4).
The two regions contributing the greatest number of popula-
tion-based families were Scotland (n = 21) and North America 
(n = 27). We estimated that the cumulative risk to age 70 years for 
Scottish men and women who were MSH6 mutation carriers was 
33% (95% CI = 17% to 54%) and 15% (95% CI = 7% to 32%), 
respectively, compared with the corresponding cumulative risks 
for North American MSH6 mutation carriers of 18% (95% 
CI = 8% to 36%) and 4% (95% CI = 1% to 21%), respectively. 
These differences in cumulative risk by geographic region were 
not, however, statistically significant (P = .4).
For MSH6 mutation carriers, the estimated risks for colorectal 
cancer among men relative to those among men in the general 
population (HR = 8.6, 95% CI = 5.5 to 13.4) were not statistically 
significantly different from those among women (HR = 6.4, 95% 
CI = 3.6 to 11.4; P = .4). When we combined men and women who 
were MSH6 mutation carriers, the increased risk for colorectal 
cancer, relative to that of the general population, over all ages was 
Table 1. Data for the penetrance analysis by country and ascertainment method of recruitment of the proband
Region
Population-based ascertainment Clinic-based ascertainment
No. of families Estimated No. of carriers* No. of families Estimated No. of carriers*
United States† 24 182 7 93
Canada† 3 35 2 23
Australia 0 — 15 88
Scotland 21 130 0 —
Netherlands 0 — 41 493
Total 48 346 65 697
* Values were based on genetic relatedness to known MSH6 mutation carriers and noncarriers. The values do not include probands.
† Three Canadian and three US families had population-based ascertainment but were treated in analysis as ascertained on family history because of sampling 
method used.
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statistically significantly elevated (HR = 7.6, 95% CI = 5.4 to 10.8; 
P < .001). There was some evidence, although not statistically 
significant (P = .15), that the risk for colorectal cancer among car-
riers younger than 50 years relative to similarly aged men and 
women in the population (HR = 12.0, 95% CI = 6.4 to 22.8) was 
higher than that for carriers 50 years or older relative to similarly 
aged men and women in the population (HR = 6.5, 95% CI = 4.2 to 
10.0). There was little statistical evidence that the increased risk to 
carriers differed by mutation type (P > .3) or whether the proband 
was ascertained from a population-based source independent of 
their family history (HR = 7.8, 95% CI = 5.3 to 17.4) or from a 
family cancer clinic (HR = 4.5, 95% CI = 2.3 to 9.0) (P for 
difference = .5).
We estimated that 26% (95% CI = 18% to 36%) and 44% (95% 
CI = 30% to 58%) of women would be diagnosed with endometrial 
cancer by ages 70 and 80 years, respectively. The 10-year risk of 
endometrial cancer for MSH6 mutation carriers without a previous 
endometrial cancer diagnosis at age 70 years was 24% (95% 
CI = 14% to 36%). The 10-year risks at other ages were 7% (95% 
CI = 5% to 11%) at age 50 years and 14% (95% CI = 9% to 21%) 
at age 60 years (Table 4). MSH6 mutation carriers who were 
women had an endometrial cancer risk that was about 25 times 
higher than women in the general population (HR = 25.5, 95% 
CI = 16.8 to 38.7; P < .001).
MSH6 mutation carriers who were women had a cumulative 
risk of at least one cancer of the ovary, stomach, small intestine, 
Table 2. Characteristics of individuals with cancer known to be MSH6 mutation carriers and of individuals with an MSH6 mutation 
carrier probability of 0.25 or higher (excluding probands) in MSH6 mutation-carrying families by ascertainment
Cancer Sex
Population-based families (n = 48) Clinic-based families (n = 65)
No. of diagnoses
Mean age  
at diagnosis,  
y (SD)
Median age  
at diagnosis,  
y (range) No. of diagnoses
Mean age  
at diagnosis,  
y (SD)
Median age 
at diagnosis, 
y (range)
Colorectal Male 24 62.6 (9.8) 59 (47–85) 69 56.1 (13.3) 58 (30–85)
Female 13 60.7 (15.1) 60 (36–82) 42 56.8 (12.3) 56 (30–90)
Endometrial Female 22 53.9 (11.7) 51 (32–80) 49 53.4 (9.8) 53 (33–82)
Other Lynch cancers Male 6 51.2 (7.6) 51 (43–65) 15 60.9 (15.1) 57 (32–84)
Female 13 55.4 (9.4) 55 (39–72) 13 46.1 (14.8) 46 (21–75)
 Ovary Female 8 52.2 (9.6) 52 (39–72) 4 41.0 (10.2) 44 (27–49)
 Stomach Male 5 52.2 (8.0) 51 (43–65) 8 65.6 (14.4) 61 (43–84)
Female 3 63.0 (2.6) 64 (60–65) 2 54.0 (5.7) 54 (50–58)
 Small intestine Male 0 —  1 40.0 (—) 40
Female 0 —  0 —
 Kidney Male 0 —  2 69.5 (9.2) 69 (63–76)
Female 1 65.0 (—) 65 3 52.3 (19.7) 43 (39–75)
 Ureter Male 0 —  1 59.0 (—) 59
Female 0 —  0 —
 Brain Male 1 46 46 3 50.3 (16.8) 54 (32–65)
Female 1 48 48 4 42.5 (19.4) 43 (21–67)
Total Lynch cancers Male 30 60.3 (10.5) 60 (43–85) 84 56.9 (13.4) 57 (30–85)
Female 48 56.1 (12.3) 55 (32–82) 104 53.9 (11.8) 54 (21–90)
Other cancers* Male 34 56.8 (16.3) 60 (16–80) 42 65.3 (14.9) 64 (19–89)
Female 33 59.7 (16.1) 60 (26–85) 28 57.6 (16.9) 55 (35–87)
Total cancers Male 64 58.4 (13.8) 60 (16–85) 126 59.7 (14.4) 59 (19–89)
Female 81 57.6 (13.9) 57 (26–85) 132 54.7 (13.0) 54 (21–90)
* Other cancers include lung (n = 28), breast (n = 25), skin (n = 13), prostate (n = 10), pancreas (n = 6), bladder (n = 6), testis (n = 5), liver (n = 4), thyroid (n = 4), pharynx 
(n = 3), larynx (n = 2), bone (n = 2), myeloma (n = 2), leukemia (n = 5), lymphoma (n = 2), eye (n = 1), mouth (n = 1), biliary tree (n = 1), and unspecified (n = 14).
Table 3. Age-specific cumulative risk from birth (95% confidence intervals [CIs]) for cancer in MSH6 mutation carriers, for cancer by sex
Cancer type Sex
Age-specific cumulative risk, % (95% CI)
50 y 60 y 70 y 80 y
Colorectal cancer Male 3 (1 to 7) 9 (5 to 14) 22 (14 to 32) 44 (28 to 62)
Female 2 (1 to 5) 5 (2 to 9) 10 (5 to 17) 20 (11 to 35)
Endometrial cancer Female 7 (4 to 11) 14 (9 to 20) 26 (18 to 36) 44 (30 to 58)
Other Lynch cancers* Male 1 (0 to 6) 2 (0 to 8) 3 (1 to 14) 6 (1 to 25)
Female 2 (1 to 5) 5 (3 to 9) 11 (6 to 19) 22 (12 to 38)
Any Lynch cancer Male 4 (2 to 9) 10 (6 to 18) 24 (16 to 37) 47 (32 to 66)
Female 11 (7 to 16) 22 (16 to 30) 40 (32 to 52) 65 (53 to 78)
Other cancers Male 4 (2 to 9) 9 (5 to 16) 18 (11 to 29) 33 (19 to 51)
Female 3 (1 to 6) 6 (3 to 12) 15 (9 to 23) 30 (17 to 47)
Any cancer Male 8 (5 to 15) 18 (13 to 27) 38 (28 to 51) 65 (51 to 80)
Female 13 (9 to 19) 27 (21 to 35) 49 (41 to 60) 75 (65 to 86)
* Other Lynch cancers include cancers of the kidney, stomach, ovary, small bowel, ureter, and brain.
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kidney, ureter, or brain of 11% (95% CI = 6% to 19%) by age 70 
years and 22% (95% CI = 12% to 38%) by age 80 years. They were 
at six times the population risk of Lynch syndrome cancers other 
than colorectal and endometrial cancers compared with the gen-
eral population (HR = 6.0, 95% CI = 3.4 to 10.7; P < .001). There 
was no evidence for an increased risk of these cancers for MSH6 
mutation carriers who were men (HR = 0.8, 95% CI = 0.1 to 8.8; 
P = .9).
There was no evidence for an increased risk of breast cancer 
(HR = 0.6, 95% CI = 0.2 to 1.6; P = .3), prostate cancer (HR = 0.2, 
95% CI = 0.0 to 1.2; P = .08), or any non-Lynch syndrome cancers 
among men or women. Overall, among those who carry an MSH6 
mutation, we estimate that 24% (95% CI = 16% to 37%) of men 
and 40% (95% CI = 32% to 52%) of women will be diagnosed with 
any Lynch syndrome cancer by age 70 years and that these values 
will increase to 47% (95% CI = 32% to 66%) of men and 65% 
(95% CI = 53% to 78%) of women by age 80 years.
Discussion
We have assembled, to our knowledge, the largest series of MSH6 
mutation carrier families that has been used to estimate penetrance 
to date. Among MSH6 mutation carriers, we estimated that ap-
proximately three in 10 men and one in 10 women will be diag-
nosed with colorectal cancer by age 70 years and that four in 10 
men and two in 10 women will be diagnosed with colorectal cancer 
by age 80 years. In contrast to our findings, a meta-analysis (18) of 
Table 4. Risk of cancer in 10-year intervals for MSH6 mutation 
carriers at ages 50, 60, and 70 years who have had no previous 
diagnosis of the cancer (or group of cancers) at the beginning of 
the 10-year period*
Cancer Sex
10-y cancer risk at age, % (95% CI)
50 y 60 y 70 y
Colorectal cancer Male 6 (3 to 9) 14 (8 to 22) 28 (16 to 45)
Female 3 (1 to 5) 6 (3 to 11) 11 (4 to 23)
Endometrial Female 7 (5 to 11) 14 (9 to 21) 24 (14 to 36)
Any Lynch cancer† Male 6 (4 to 10) 15 (9 to 24) 31 (17 to 48)
Female 12 (9 to 17) 24 (17 to 33) 41 (29 to 55)
* For example, a man with no previous colorectal cancer diagnosis at age 70 
years has a 28% risk for development of a colorectal cancer by age 80 years.
† Any Lynch cancers include cancers of the colorectum, endometrium, kidney, 
stomach, ovary, small bowel, ureter, and brain.
Figure 1. Age-specific cumulative risks from birth of Lynch syndrome 
cancers for carriers of MSH6 mutations. CRC = colorectal cancer.
extracted data from just 10 families in two studies (17,20) predicted 
that three in 10 carriers would be diagnosed with colorectal cancer 
by age 70 years, with no difference between men and women, and 
also observed no increase in colorectal cancer risk after age 70 
years. We estimated that three in 10 MSH6 mutation carriers who 
were women will be diagnosed with endometrial cancer by age 70 
years and that four of the 10 carriers will be diagnosed by age 80 
years, whereas the meta-analysis (18) estimated that approximately 
three of the 10 carriers will be diagnosed with endometrial cancer 
by age 70 years and five of the 10 carriers will be diagnosed by age 
80 years.
How do these estimates compare with those for mutations in 
the other mismatch repair genes—MLH1, MSH2, and PMS2? A 
meta-analysis (18) of three population-based studies (5,20,31) and 
one clinic-based study (24) estimated that the risk of colorectal 
cancer for MLH1 and MSH2 carriers was 53% for men and 33% 
for women (compared with 22% and 10%, respectively, for MSH6 
mutation carriers in this study), and the risk of endometrial cancer 
was 44% (compared with 26% for MSH6 mutation carriers in this 
study) with no substantial increases from age 70 years to age 80 
years (compared with a 10-year colorectal cancer risk at age 70 
years of 28% among carriers who were men and 11% among car-
riers who were women in this study, albeit with large confidence 
intervals). For carriers of PMS2 mutations, the risk of colorectal 
cancer to age 70 years was 20% among men and 15% among 
women and the risk of endometrial cancer was 15% (32).
The major strengths of this study are the size and the statistical 
methods that we used, which have resulted, to our knowledge, in 
the most precise and unbiased estimates produced to date and, 
therefore, of most clinical use of all published estimates. We 
acknowledge that penetrance may depend on the MSH6 mutation, 
the country in which the carrier lives, and other genetic and envi-
ronmental modifiers of risk; and thus, we have presented the av-
erage penetrance of all identified mutations across several countries. 
There was no statistical evidence of heterogeneity of the pene-
trance by geographic region when comparing those of Scotland 
with those of North America. A substantial proportion of the fam-
ilies for this analysis were ascertained because of a relative diag-
nosed with colorectal cancer at an early age; therefore, these 
results may be more generalizable to MSH6 mutation carriers who 
have a family history of early-onset disease.
A limitation of this study was that no haplotype analysis was 
done for any of the mutations identified in more than one family, 
and so it was not possible to conclude founder mutation status. 
However, mutation c.651_652insT was identified in five of the 
clinic-based families from the Netherlands; mutation c.1784delT 
was identified in four clinic-based families from the Netherlands; 
and mutation c.3939_3958dup19 was identified in three popula-
tion-based families from Scotland, which is consistent with a 
common founder for each of these mutations.
The findings of this study indicate that the screening recommen-
dations for MSH6 mutation carriers may vary slightly from those 
previously published for Lynch syndrome as a whole (Table 5). We 
have shown that the risk for colorectal cancer and endometrial cancer 
continued to increase between the ages of 70 and 80 years, although 
the confidence intervals for the 10-year risks are large. Our data 
suggest that screening for colorectal cancers should likely continue 
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Table 5. Management for at-risk members of Lynch syndrome families with MSH6 mutation
Management
Recently published  
recommendations for Lynch 
syndrome as a whole
Levels of certainty* regarding  
net benefit for Lynch syndrome 
as a whole
Recommendations for  
MSH6 mutation carriers by 
authors of this article
Cancer screening options
 Colonoscopy Every 1–2 y beginning at age 20–25  
 y (age 30 y in MSH6 families) or  
 10 y younger than the youngest age  
 at diagnosis in the family, whichever  
 comes first (33); every 1–2 y starting  
 at age 20–25 y for men and age 30 y  
 for women (34); every 1–2 y starting  
 at ages 20–25 y (3)
High† Every 1–2 y beginning at age  
 30 y‡
 Endometrial sampling Every year beginning at age 30–35 y  
 (33); every 1–2 y starting between  
 ages of 30 and 35 y (34)
Moderate (when combined with  
 transvaginal ultrasound) (35)
Every year beginning at age  
 30–35 y‡
 Transvaginal ultrasound for  
  endometrial and ovarian  
  cancers
Every year beginning at age 30–35 y  
 (33); every 1–2 y starting at age  
 30–35 y (34); every 1–2 y starting  
 between ages of 30 and 35 y (3)
Poor Every year beginning at age  
 30–35 y. Role of serological  
 markers for ovarian cancer  
 screening is uncertain
 Urinalysis with cytology Every 1–2 y beginning at age 25–35 y  
 (33) or beginning at age 50 y (34);  
 every 1–2 y starting between ages of  
 30 and 35 y if urinary tract cancer runs  
 in family (3)
Poor Consider every 1–2 y beginning 
 at age 40 y
 Gastroduodenoscopy “Could be offered periodically” (33);  
 every 1–2 y starting at age 30–35 y  
 if it occurs two or more times in  
 the family (34); every 1–2 y starting  
 between ages of 30 and 35 y if gastric  
 cancer runs in family or in countries  
 with high incidence of gastric cancer (3)
Poor No evidence of increased risks  
 except by analogy to other  
 genes causing Lynch  
 syndrome
Surgical considerations
 Colorectal resection (segmental  
  vs subtotal colectomy vs  
  complete proctocolectomy)
For at-risk persons without colorectal  
 cancer: generally not advised.  
 Discuss as alternative, with  
 preferences of well-informed patient  
 actively elicited. For persons with a  
 diagnosis of colorectal cancer or polyp  
 not resectable by colonoscopy, subtotal  
 colectomy favored with preferences of  
 the well-informed patient actively  
 elicited (33). The option of extensive  
 resection should be discussed with  
 patients younger than 50 y at colorectal  
 cancer diagnosis (3)
Poor No change in recommendations
 Hysterectomy or salpingo- 
  oophorectomy
Discuss as option after childbearing  
 completed (33); may be an option for  
 women as it substantially reduces  
 site-specific cancers (3)
Moderate No change in recommendations
* The United States Preventative Services Task Force changed its grade definitions on the basis of a change in methods in May 2007 (36).
† Quality of evidence supports colon examination, but optimal frequency and initiation age have not been adequately addressed.
‡ In the cohort of relatives of the MSH6 mutation families, three (1.2%) of the 241 colorectal cancer diagnoses occurred at or before age 30 years, zero of the 129 
endometrial cancer diagnoses occurred at or before age 30 years, and seven (5.4%) of the 129 endometrial cancer diagnoses were diagnosed between ages of 
30 and 35 years.
into advanced years, being discontinued only when the risk of the 
procedures outweighs the risk of development of a cancer. Careful 
discussion between doctor and patient will be required to reach an 
optimal decision on when or if that point has been reached.
For the management of gynecological cancers, the evidence sup-
porting the use of screening is moderate to poor (35) and, therefore, 
underscores the consideration of risk-reducing bilateral salpingo-
oophorectomy and hysterectomy at a premorbid age. Endocervical 
stenosis may render annual endometrial sampling increasingly diffi-
cult in many postmenopausal women. Cancer screening and preven-
tion in men and women with Lynch syndrome remain a subject in 
flux, with much promise of noninvasive screening on the horizon for 
some cancers including ovarian (37) and urothelial (38) cancers.
In conclusion, by aggregating data from 113 families that 
contained approximately 1000 mutation carriers from five 
countries and analyzing the data with statistical methods that 
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allow for conditioning on ascertainment, we have provided the 
most precise cancer-specific estimates of penetrance to date for 
carriers of MSH6 mutations. These results demonstrate that the 
elevated risks for cancers in MSH6 mutation carriers differ by 
sex of the carrier and continue into older age.
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